Biogen
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
The current Biogen(BIIB) stock price is $217.61, with a market capitalization of 32.15B. The stock trades at a price-to-earnings (P/E) ratio of 37.96.
On 2026-08-21, Biogen(BIIB) stock moved within a range of $215.00 to $219.12. With shares now at $217.61, the stock is trading +1.2% above its intraday low and -0.7% below the session's peak.
Trading activity shows a volume of 310.83K, compared to an average daily volume of 769.5K.
The stock's 52-week range extends from a low of $131.52 to a high of $222.15.
The stock's 52-week range extends from a low of $131.52 to a high of $222.15.
BIIB News
Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident i...
Biogen (BIIB) is back in focus after recent share price moves and fresh attention on its neurology focused drug portfolio. Investors are weighing current perfor...
Analyst ratings
67%
of 36 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.